188K shares changed hands on Tuesday. Volume was down 83.91% under the stocks average daily volume.
Investors are feeling more bearish on Viking Therapeutics, Inc. if you take into consideration the rise in short interest. The company recorded a rise in short interest of 214.17% as of October 13, 2017 from the last reporting period. Short shares grew from 319,148 to 1,002,683 over that period. The days to cover decreased to 1.0 and the short interest percentage is 0.04% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Morgan Stanley had disposed of 15,241 shares trimming its position 97.5%. The value of the investment in Viking Therapeutics, Inc. decreased from $19,000 to $1,000 decreasing 94.7% for the reporting period. Manufacturers Life Insurance Company, The augmented its ownership by buying 182 shares an increase of 10.1% as of 06/30/2017. Manufacturers Life Insurance Company, The owns 1,989 shares with a value of $2,000. The value of the position overall is down by 33.3%.
Grt Capital Partners L.l.c. reduced its holdings by shedding 18,408 shares a decrease of 17.7%. Grt Capital Partners L.l.c. currently owns 85,570 shares valued at $92,000. The total value of its holdings decreased 39.5%. As of quarter end Renaissance Technologies LLC had bought a total of 33,200 shares growing its holdings by 12.5%. The value in dollars went from $388,000 to $323,000 a change of $65,000 quarter over quarter.
The company is so far trading up since yesterday’s close of $2.38. Shares last traded at $2.38 which is significantly higher than the 50 day moving average which is $1.97 and impressively higher than the 200 day moving average of $1.95. The 50 day moving average went up by +20.76% whereas the 200 day average was up by +22.12%.
In the latest earnings report the EPS was $-0.83 and is expected to be $-0.83 for the current year with 27,697,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.18 and the next full year EPS is projected to be $-0.80.
Viking Therapeutics, Inc., launched on October 24, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Business’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). The Business’s second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. VK2809 belongs to a family of prodrugs, which are cleaved in vivo to release potent thyromimetics. The Company is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). X-ALD is an X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease is caused by mutations in a peroxisomal transporter of very long chain fatty acids (VLCFA), known as the adenosine triphosphate binding cassette transporter D1, or ABCD1..